Lipid Lowering Combination Therapy for Dyslipidemia

Prof. Maciej Banach is a Vice-Rector for Collegium Medicum in the John Paul II Catholic University of Lublin (KUL) and Head of Department of Preventive Cardiology and Lipidology at the Medical University of Lodz (MUL). He is also an Adjunct Professor at the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, and Senior Research Fellow at the Liverpool Centre for Cardiovascular Sciences (LCCS). He is a Founder and Head of the Polish Lipid Association (PoLA), Founder of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group, and President of the International Lipid Expert Panel (ILEP). Prof. Banach is within 1% the highest cited scientists in the world according to Essential Science Indicators by Clarivate (with 83 TOP Papers) and one of the most cited scientist in Poland. He is a laureate of several prizes and award, including: the Most Influential Person in Medicine in Poland for year 2023 with 2nd place for year 2024 on the Top 100 list by Puls Medycyny journal, and 5 recognitions of Doctor Honoris Causa (at the Universities in Zagreb, Kosice, Bucharest, Kiev, and Timisoara).

• I. Epidemiology and Prevalence of Lipid DisordersII. Lipid Disorders: Cardiovascular Risk and Disease Progression1. Causal link between hypercholesterolemia and cardiovascular disease risk and mortality2. Lipid disorders and atherosclerosis/atheroma plaque progression and vulnerability3. Residual cardiovascular risk related to lipid disordersIII. Diagnostic Approaches and Emerging Biomarkers in Lipid Disorders4. Current guidelines on lipid disorders diagnosis5. New lipid targets and their role in lipid disordersIV. Therapeutic Strategies and Guidelines in Lipid Management6. The concept of the combination lipid lowering therapy for hypercholesterolemia7. Risk stratification methods and imaging methods to support decision on lipid lowering therapy intensification8. Use of Combination Statin and Bile Acid Sequestrant Therapy to Treat Dyslipidemia - is there any place for this?9. Statins and Niacin: is this really an end?10. Statins and Ezetimibe – synergistic power to fight against hypercholesterolemia?11. Statins and bempedoic acid – not only statin intolerant patients!12. Statins and PCSK9 Inhibitors: Why still so limited?13. Statins and inclisiran – lets define the most suitable patients waiting for CVOT data14. Statins and CETP Inhibitors: a game-changer reborn?15. Lipid lowering combination therapy for patients with familial hypercholesterolemia  15.1. Statins and Mipomersen: Mechanisms of Action and Patient Tolerability  15.2. Statins and Lomitapide: A Suitable Response for Homozygous Familial Hypercholesterolemia?  15.3. Statins and Evinacumab – what patients may benefit the most16. Lipid lowering combination therapy for statin intolerant patients17. Other perspective drugs for hypercholesterolemia (oral PCSK9, Lerodalcibep, and others)18. Lipid lowering combination therapy for hypertriglicerydemia  18.1. Statins and fenofibrate: Still effective and underused  18.2. The Role of Omega-3 Fatty Acids in Dyslipidemias  18.3. New drugs for HTG and SHTG: volanesorsen, olezarsen, pegozafermin, plozasiran, and solbinsiran19. Recommendations for elevated Lp(a) diagnosis and management  19.1. Pelacarsen  19.2. Muvalaplin  19.3. SiRNA therapies – Olpasiran, lepodisiran and zerlasiran20. Lipid-Lowering Therapy and Apheresis: Indications and Outcomes21. Personalized combination LLT in patients with metabolic disorders22. The concept of the upfront combination LLT – the waiting gold standard to fight against hypercholesterolemia23. Single pill combination – the more frequent the better to effectively prevent cardiovascular health24. Combination of Lipid-Lowering Agents with Antihypertensive Drugs: A Joint Fight Against the Two Most Important Risk Factors?25. Combination of Lipid-Lowering Agents with Aspirin – is there a place in primary prevention patients?26. Other existing, perspective or expected combination therapies to improve CVD preventionV. Innovation and Future Directions in Lipid-Lowering TherapiesVI. Summary, Clinical Implications, and Future Perspectives